---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-105733"
form_type: "8-K/A"
ticker: "ABPO"
cik: "0001893219"
company_name: "Abpro Holdings, Inc."
filed_at: "2025-11-04T23:59:59+00:00"
generated_at: "2026-05-17T00:43:30.620884+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Abpro/Celltrion present preclinical data for CT-P72/ABP-102 at SITC 2025; poster in top 150

## Summary
- Poster selected as one of Top 150 abstracts out of >1,300 submissions at SITC 2025.
- CT-P72/ABP-102 demonstrated potent anti-tumor activity in HER2-high models, including Enhertu-resistant tumors.
- Dual-affinity engineering reduced on-target/off-tumor activity; favorable safety in non-human primates.
- Data supports advancement toward IND and first-in-human trial planned for next year.
- Built on Abpro's DiversImmune® platform for rapid engineering of next-generation antibodies.

## SEC filing metadata
- accession: 0001213900-25-105733
- form_type: 8-K/A
- ticker: ABPO
- cik: 0001893219
- company_name: Abpro Holdings, Inc.
- filed_at: 2025-11-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1893219/000121390025105733/0001213900-25-105733-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1893219/000121390025105733/ea0263868-8ka1_abpro.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-105733
- JSON: https://secwatch.observer/filing/0001213900-25-105733.json
- Plain text: https://secwatch.observer/filing/0001213900-25-105733.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.